Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEB-01 in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma
NCT04619056Phase 1Completed
- Sponsor
- Cebiotex
- Start
- Jun 2020
- Primary completion
- Nov 2025
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CEB-01 in retroperitoneal soft tissue sarcoma (RPS) (3 cohorts), sponsored by Cebiotex. Primary endpoint: Recommended Doses for Phase II (Maximum tolerated dose) at 2 weeks. Started Jun 2020; status: completed.
02
Drugs
CEB-01
03
Conditions
retroperitoneal soft tissue sarcoma (RPS)
Beyond the preview
Go deeper on NCT04619056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619056.